First-Line Breast Cancer Approval Opens The Door For Pfizer’s Palbociclib
This article was originally published in The Pink Sheet Daily
Executive Summary
The CDK 4/6 inhibitor Ibrance (palbocliclib) just got its first approval in first-line metastatic breast cancer and Pfizer is losing no time on development, with trials of other indications planned or ongoing, including different tumor types.